[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 6 of about 6
1. Sorianello E, Schillaci R, Chamson-Reig A, Lux-Lantos V, Libertun C: Actions of immunosuppressor drugs on the development of an experimental ovarian tumor. Exp Biol Med (Maywood); 2002 Sep;227(8):658-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Actions of immunosuppressor drugs on the development of an experimental ovarian tumor.
  • Immunosuppression has been related to the incidence of tumor apparition, including endocrine tumors.
  • The intrasplenic ovarian tumor (luteoma) is a typical benign endocrine tumor that develops under high gonadotropin stimulation and, from the immunological perspective, is located in a critical organ involved in immune response.
  • To establish if immunosuppression could alter the development of this experimental tumor, the effects of cyclosporin A (CsA) and dexamethasone (Dex) were evaluated.
  • After surgery, tumor-bearing and sham animals were kept without treatment for 4 weeks; thereafter, they were distributed into CsA (25 mg/kg), Dex (0.1 mg/kg), or vehicle (75:25 castor oil:ethanol) groups and were injected on alternate days for 50 days.
  • Animals were sacrificed after a jugular vein blood sample was obtained.
  • Tumors were measured and placed in formaline for histological studies.
  • CsA induced a significant decrease in survival rates both in tumor-bearing and sham animals (P < 0.01).
  • Dex significantly impaired weight increase in both groups of animals.
  • CsA induced a significant weight loss in sham animals, not observed in tumor-bearing animals.
  • Dex induced thymus weight loss in both groups, whereas CsA induced thymus weight loss only in sham animals.
  • CsA induced an increase in monocyte number only in sham animals.
  • Neither Dex nor CsA induced any significant variations in tumor volume, nor did they alter tumor histology.
  • We conclude that, though immunological parameters were altered by the treatments, immunosuppressor drugs did not condition tumor development.
  • In addition, tumors secrete one or more factor/s that counteract CsA effect.
  • [MeSH-major] Cyclosporine / pharmacology. Dexamethasone / pharmacology. Immunosuppressive Agents / pharmacology. Luteoma / pathology. Ovarian Neoplasms / pathology. Spleen / pathology
  • [MeSH-minor] Animals. Body Weight / drug effects. Estradiol / blood. Female. Follicle Stimulating Hormone / blood. Immunocompromised Host. Luteinizing Hormone / blood. Neoplasm Transplantation. Organ Size / drug effects. Ovariectomy. Ovary / transplantation. Prolactin / blood. Rats. Rats, Sprague-Dawley. Thymus Gland / pathology. Transplantation, Heterotopic

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • Hazardous Substances Data Bank. MENOTROPINS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12192110.001).
  • [ISSN] 1535-3702
  • [Journal-full-title] Experimental biology and medicine (Maywood, N.J.)
  • [ISO-abbreviation] Exp. Biol. Med. (Maywood)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 4TI98Z838E / Estradiol; 7S5I7G3JQL / Dexamethasone; 83HN0GTJ6D / Cyclosporine; 9002-62-4 / Prolactin; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


2. Grandi F, Colodel MM, Monteiro LN, Leão JR, Rocha NS: Extramedullary hematopoiesis in a case of benign mixed mammary tumor in a female dog: cytological and histopathological assessment. BMC Vet Res; 2010;6:45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extramedullary hematopoiesis in a case of benign mixed mammary tumor in a female dog: cytological and histopathological assessment.
  • BACKGROUND: Extramedullary hematopoiesis (EMH) is defined as the presence of hematopoietic stem cells such as erythroid and myeloid lineage plus megakaryocytes in extramedullary sites like liver, spleen and lymph nodes and is usually associated with either bone marrow or hematological disorders.
  • Mammary EMH is a rare condition either in human and veterinary medicine and can be associated with benign mixed mammary tumors, similarly to that described in this case.
  • CASE PRESENTATION: Hematopoietic stem cells were found in a benign mixed mammary tumor of a 7-year-old female mongrel dog that presents a nodule in the left inguinal mammary gland.
  • Histological examination confirmed the presence of an active hematopoietic bone marrow within the bone tissue of a benign mammary mixed tumor.
  • CONCLUSIONS: EMH is a rare condition described in veterinary medicine that can be associated with mammary mixed tumors.
  • It's detection can be associated with several neoplastic and non-neoplastic mammary lesions, i.e. osteosarcomas, mixed tumors and bone metaplasia.
  • [MeSH-minor] Animals. Biopsy, Fine-Needle / veterinary. Blood Cell Count / veterinary. Dogs. Female. Hematocrit / veterinary. Hemoglobins / analysis. Histocytochemistry / veterinary. Mastectomy / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2001 Feb;12(2):267-70 [11300336.001]
  • [Cites] Vet Clin Pathol. 2009 Dec;38(4):521-8 [19392751.001]
  • [Cites] Am J Surg Pathol. 1980 Jun;4(3):281-5 [7396068.001]
  • [Cites] Diagn Imaging. 1982;51(1):19-24 [7060437.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1983;401(2):203-7 [6415904.001]
  • [Cites] Blood. 1985 Apr;65(4):803-9 [3978228.001]
  • [Cites] Vet Pathol. 1986 Nov;23(6):649-55 [3811129.001]
  • [Cites] J Comput Assist Tomogr. 1987 May-Jun;11(3):541-2 [3571606.001]
  • [Cites] J Comp Pathol. 1989 Nov;101(4):443-50 [2607016.001]
  • [Cites] J Clin Ultrasound. 1993 Nov-Dec;21(9):631-5 [8227393.001]
  • [Cites] Vet Pathol. 1995 Jul;32(4):437-40 [7483223.001]
  • [Cites] Pathol Res Pract. 1997;193(3):219-22; discussion 223-4 [9198107.001]
  • [Cites] Head Neck. 1998 May;20(3):204-7 [9570625.001]
  • [Cites] Vet J. 1999 Jul;158(1):39-47 [10409415.001]
  • [Cites] J Clin Pathol. 2005 Apr;58(4):448 [15790723.001]
  • [Cites] Ann Clin Lab Sci. 2006 Autumn;36(4):475-8 [17127738.001]
  • [Cites] Cytopathology. 2007 Jun;18(3):191-6 [17573766.001]
  • [Cites] BMC Cancer. 2007;7:218 [18045453.001]
  • [Cites] Prev Vet Med. 2001 Sep 20;51(1-2):125-36 [11530199.001]
  • (PMID = 20846427.001).
  • [ISSN] 1746-6148
  • [Journal-full-title] BMC veterinary research
  • [ISO-abbreviation] BMC Vet. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hemoglobins
  • [Other-IDs] NLM/ PMC2954924
  •  go-up   go-down


3. Chou YH, Chiou HJ, Tiu CM, Chiou SY, Hsia CY, Tsay SH: Splenic hamartoma: presentation on contrast-enhanced sonography. J Clin Ultrasound; 2004 Oct;32(8):425-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Splenic hamartoma: presentation on contrast-enhanced sonography.
  • Splenic hamartoma is a rare benign tumor of the spleen.
  • We report a case of splenic hamartoma that was discovered during medical workup for vague upper abdominal pain.
  • Abdominal sonography demonstrated a well-demarcated, slightly hypoechoic splenic solid mass; the mass was markedly enhanced on color Doppler sonography after injection of microbubble contrast agent.
  • This finding may help to distinguish splenic hamartomas from other relatively common splenic tumors, such as hemangiomas or metastases.
  • [MeSH-major] Hamartoma / ultrasonography. Splenic Diseases / ultrasonography
  • [MeSH-minor] Contrast Media. Diagnosis, Differential. Humans. Male. Middle Aged. Polysaccharides

  • MedlinePlus Health Information. consumer health - Spleen Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley Periodicals, Inc.
  • (PMID = 15372453.001).
  • [ISSN] 0091-2751
  • [Journal-full-title] Journal of clinical ultrasound : JCU
  • [ISO-abbreviation] J Clin Ultrasound
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Polysaccharides; 127279-08-7 / SHU 508
  •  go-up   go-down


Advertisement
4. Wang J, Maitani Y, Takayama K: Antitumor effects and pharmacokinetics of aclacinomycin A carried by injectable emulsions composed of vitamin E, cholesterol, and PEG-lipid. J Pharm Sci; 2002 Apr;91(4):1128-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The acute toxicity, antitumor effects, and pharmacokinetics of E-ACM were studied in C57BL/6 mice bearing mouse murine histiocytoma M5076 tumors.
  • The heart, lung, and kidney AUC(0.03-48h) of E-ACM were significantly smaller than those of F-ACM whereas the liver and spleen AUC(0.03-48h) of E-ACM were not significantly different from those of F-ACM.
  • The tumor AUC(0.03-48h) of E-ACM was significantly greater than that of F-ACM.
  • E-ACM had lower acute toxicity and greater potential antitumor effects than F-ACM in M5076 tumor-bearing C57BL/6 mice.
  • E-ACM is a useful tumor-targeting drug delivery system.
  • [MeSH-major] Aclarubicin / pharmacokinetics. Antibiotics, Antineoplastic / pharmacokinetics. Antioxidants / pharmacokinetics. Cholesterol / pharmacokinetics. Histiocytoma, Benign Fibrous / drug therapy. Polyethylene Glycols / pharmacokinetics. Vitamin E / pharmacokinetics
  • [MeSH-minor] Animals. Drug Carriers / pharmacokinetics. Drug Carriers / pharmacology. Emulsions / administration & dosage. Emulsions / pharmacokinetics. Emulsions / toxicity. Injections, Intraperitoneal. Injections, Intravenous. Injections, Subcutaneous. Male. Mice. Mice, Inbred C57BL. Particle Size. Tumor Cells, Cultured / drug effects. Tumor Cells, Cultured / metabolism. Tumor Cells, Cultured / transplantation

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Cholesterol.
  • MedlinePlus Health Information. consumer health - Vitamin E.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley-Liss, Inc. and the American Pharmaceutical Association J Pharm Sci 91:1128-1134, 2002
  • (PMID = 11948551.001).
  • [ISSN] 0022-3549
  • [Journal-full-title] Journal of pharmaceutical sciences
  • [ISO-abbreviation] J Pharm Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antioxidants; 0 / Drug Carriers; 0 / Emulsions; 1406-18-4 / Vitamin E; 30IQX730WE / Polyethylene Glycols; 74KXF8I502 / Aclarubicin; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


5. Kubota N, Kojima T, Naruse T: Effect of hemostatics used during operations for digestive organ on cancer cells present in the peritoneal cavity. Cancer Biother Radiopharm; 2000 Feb;15(1):47-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We investigated effects of hemostatics used during operations for digestive organ on cancer cells present in the peritoneal cavity using BALB/c mice inoculated with Meth A tumor cells (fibrosarcoma) intraperitoneally (i.p.) and C3H/He mice inoculated with MH134 tumor cell (hepatic cell carcinoma) i.p.
  • Microfibrillar collagen hemostat (Avitene) or fibrinogen preparation (Beriplast P) did not affect survivals of those tumor-bearing mice.
  • Gelatin sponge (Spongel)prolonged survivals of MH134 tumor-bearing mice.
  • Liquid form gelatin used instead of Spongel displayed in vitro antitumor effect on MH134 tumor cells at the concentration of 15 mg/ml.
  • Radioactive sodium chromate-labeled MH134 and Meth A tumor cells were not lysed when they were incubated with 15 mg/ml of liquid form gelatin for 24 hours.
  • On the other hand, the tritium thymidine (3H-TdR) uptake by MH134 or RL male 1 tumor cells was suppressed when they were incubated with 15 mg/ml of liquid form gelatin for 24 hours.
  • Proliferation of Meth A tumor cells were not affected by the treatment.
  • Effect of liquid form gelatin on phytohemagglutinin (PHA)-stimulated spleen cells as a benign counter-part of RL male 1 tumor cells (T cell lymphoma) was examined.
  • Liquid form gelatin (15 mg/ml) did not suppress 3H-TdR uptake by PHA-stimulated spleen cells.
  • [MeSH-major] Collagen / therapeutic use. Digestive System Surgical Procedures. Fibrin Tissue Adhesive / therapeutic use. Gelatin / therapeutic use. Hemostatics / therapeutic use. Neoplasms, Experimental / drug therapy
  • [MeSH-minor] Animals. Female. Fibrosarcoma / drug therapy. Fibrosarcoma / pathology. Liver Neoplasms, Experimental / drug therapy. Liver Neoplasms, Experimental / pathology. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / pathology. Male. Mice. Mice, Inbred BALB C. Mice, Inbred C3H. Peritoneal Cavity

  • Hazardous Substances Data Bank. GELATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10740652.001).
  • [ISSN] 1084-9785
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Fibrin Tissue Adhesive; 0 / Hemostatics; 9000-70-8 / Gelatin; 9007-34-5 / Collagen
  •  go-up   go-down


6. McGregor D: Hydroquinone: an evaluation of the human risks from its carcinogenic and mutagenic properties. Crit Rev Toxicol; 2007;37(10):887-914
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This evaluation was based on inadequate evidence in humans and limited evidence in experimental animals.
  • In view of the statistical power limitations of these studies for individual diagnostic categories of cancers, they are not considered to be informative with regard to the carcinogenicity of hydroquinone.
  • Hydroquinone has been shown reproducibly to induce benign neoplasms in the kidneys of male F344 rats dosed orally either by gavage (25 and 50 mg/kg body weight) or diet (0.8%).
  • At least a portion, if not all, of the chromosomal effects are caused by interference by hydroquinone or its metabolites with chromosomal segregation, probably due to interaction with mitotic spindle proteins.
  • They included a mouse bone-marrow cell micronucleus test in which there was no genotoxic activity after exposure to a diet containing 0.8% hydroquinone for 6 days; two (32)P-post-labeling assays, one with targets of Zymbal gland, liver, and spleen in Sprague-Dawley rats, the other with the kidney as target in F344 rats; and the last oral assay was for 8-hydroxydeoxyguanosine adducts in F344 rat kidney DNA.
  • While glutathione conjugates could be responsible for the tumor induction, careful histology seems to show that the most actively toxic of several glutathione compounds tested, 2,3,5-triglutathion-S-yl hydroquinone, targets a very specific region of the kidney, the outer stripe of the outer medulla (OSOM), whereas hydroquinone-associated adenomas are more randomly distributed and occur in the cortex as well as the medulla.
  • [MeSH-minor] Animals. Carcinogenicity Tests / methods. Dose-Response Relationship, Drug. Environmental Exposure / adverse effects. Humans. Mutagenicity Tests / methods. Occupational Exposure / adverse effects. Risk Assessment

  • Hazardous Substances Data Bank. HYDROQUINONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18027166.001).
  • [ISSN] 1040-8444
  • [Journal-full-title] Critical reviews in toxicology
  • [ISO-abbreviation] Crit. Rev. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Hydroquinones; 0 / Mutagens; 123-31-9 / hydroquinone
  • [Number-of-references] 169
  •  go-up   go-down






Advertisement